
Dec 16 2025
4 min read
Antispasmodic Tablet has a market value of more than INR 1200+ crores. It is expected to rise with a CAGR of 6.5% between 2025-2030. The demand for Antispasmodic Tablet Brands in India is constantly rising. This medication is used in the top therapeutic areas. These may include Abdominal pain, IBS, Dysmenorrhea, and GI spasm. Rise in digestive disorders, High prevalence of dysmenorrhea, and other factors lead to a rise in the demand for Antispasmodic Tablet Brands. Many medical professionals want the best Antispasmodic Tablet Brands in India.
Choosing among many is ain’t a straightforward process. Therefore, this blog contains a list of the top 10 Antispasmodic Tablet Brands. These brands are manufactured or marketed by the top-rated pharma companies. Furthermore, the list below is based on brand credibility and market presence. You can choose the best tablet brand as per your business requirements. His complete list can be very informative for many pharma professionals.
Manufacturer / Marketer: Eridanus Healthcare
MIGRADON 5 is a widely used medication in many pharmacies and hospitals. It consists of Flunarizine 5 mg. This composition treats muscle spasms in the gastrointestinal and urinary tracts. Furthermore, it comes in a pack of 10*10 tablets for INR 280. Manufacturer under the proper WHO and GMP-certified manufacturing units enhances the brand’s credibility among pharma associates.
List of Top Antispasmodic Tablet Brands in India
Whether you are a distributor, stockist, or pharma professional, this list is going to be cognitively enriching. Let’s begin with the list without wasting any time.MIGRADON 5
Manufacturer / Marketer: Eridanus Healthcare
MIGRADON 5 is a widely used medication in many pharmacies and hospitals. It consists of Flunarizine 5 mg. This composition treats muscle spasms in the gastrointestinal and urinary tracts. Furthermore, it comes in a pack of 10*10 tablets for INR 280. Manufacturer under the proper WHO and GMP-certified manufacturing units enhances the brand’s credibility among pharma associates.







